Skip to main content

Table 2 Study characteristics of the two included studies

From: Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review

Study characteristics
  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis
First author Gevaert Pinto
Publication year 2013 2010
Country Belgium USA
Funding source Ghent University, Flemish Scientific Research Board, Belgian Research Fund, Interuniversity Attraction Poles Program, Global Allergy and Asthma European Network, Novartis Genentech and McHugh Research Fund, Dennis W. Jahnigen Career Development Award (American Geriatrics Society)
Study design RCT RCT
Inclusion criteria Age ≥18 with CRSwNP, comorbid asthma for >2 years, serum IgE between 30 and 700 kU/mL Age 18–75, >12 weeks of symptoms with confirmation on CT and nasal endoscopy, serum IgE between 30 and 700 kU/mL
Exclusion criteria N/A Weight >150 kg, secondary causes of CRS, contraindications to omalizumab
No. of subjects randomized 24 14
No. of subjects excluded 4 0
No. of subjects withdrawn 1 0
No. of subjects analyzed Total (n) = 23 Total (n) = 14
Men (n) = N/A Men (n) = 10
Women (n) = N/A Women (n) = 4
Age Mean = N/A Mean = 45.85
Median = N/A Median = N/A
Range = 42–56 Range = N/A
Drug dose Max dose of 375 mg 0.016 mg/kg per IU total serum IgE/mL
Dosing frequency Every 2 weeks (eight injections in total); every month (four injections in total) At enrollment and every 4 weeks for the 6 months duration
Study duration 20 weeks (16 weeks follow-up) 6 months
  1. RCT randomized controlled trial, CRS chronic rhinosinusitis, N/A not available